FDA approves bictegravir and lenacapavir for HIV - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves bictegravir and lenacapavir for HIV

The treatment was evaluated in patients receiving complex antiretroviral regimens.

  • By

  • Kathryn Wighton

  • August 28, 2026

  • 2 min

Share

  • 1

    The FDA approved bictegravir and lenacapavir (Bixlenvo) for adults with HIV-1 who have RNA levels below 50 copies/mL.

  • 2

    Bixlenvo combines bictegravir 75 mg and lenacapavir 50 mg in a once-daily tablet for HIV treatment.

  • 3

    Approval was based on phase 3 ARTISTRY-1 and ARTISTRY-2 trials showing comparable virologic suppression.

  • 4

    Participants switching to Bixlenvo reported improved fasting lipid measures and treatment satisfaction.

  • 5

    Common adverse reactions included headache, nausea, and diarrhea, with no new safety concerns identified.

Original Source(s)

FDA approves bictegravir and lenacapavir for HIV

  • by Kathryn Wighton

  • August 28, 2026

Related Content

Weekly HIV Therapy Meets Primary Endpoint

Patients who switched from daily antiretroviral therapy maintained virologic suppression in two phase 3 trials.

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

First HIV-Positive-to-HIV-Positive Lung Transplant Reported

The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.